Article

Ultra-low Input Circulating Tumor DNA Detection by MED-Amp in Early-Stage Pancreatic Cancer

2021-03-29

Abstract excerpt

<h4>Purpose</h4> The clinical utility of circulating tumor DNA (ctDNA) has been shown in advanced pancreatic ductal adenocarcinoma (PDA). However, diagnostic sensitivity of many ctDNA assays is low in resectable and locally advanced disease, where tumor burden is substantially lower. We have previously described Multiplex Enrichment using Droplet Pre-Amplification (MED-Amp), a multiplexed panel for the detection...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c70d2f93-bc44-5c1f-b688-677c6266a345
DOI: 10.1101/2021.03.28.437388

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ultra-low Input Circulating Tumor DNA Detection by MED-Amp in Early-Stage Pancreatic CancerDOI 10.1101/2021.03.28.437388Read

Multiplex Enrichment and Detection of Rare KRAS Mutations in Liquid Biopsy Samples using Digital Droplet Pre-AmplificationSemantic proximity Read

Multiplex Enrichment and Detection of Rare KRAS Mutations in Liquid Biopsy Samples using Digital Droplet Pre-AmplificationSemantic proximity Read

Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer.Semantic proximity Read

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.Semantic proximity Read

Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.Semantic proximity Read

Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancerSemantic proximity Read

Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study.Semantic proximity Read

Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer Patients Treated With Neoadjuvant Chemotherapy.Semantic proximity Read

Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinomaSemantic proximity Read

Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.Semantic proximity Read

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.Semantic proximity Read

Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinomaSemantic proximity Read